Bococizumab: Revision history

31 July 2015

• curprev 18:1018:10, 31 July 2015‎ Sergekorjian talk contribs‎ 8,137 bytes 0‎ →‎Properties
• curprev 18:1018:10, 31 July 2015‎ Sergekorjian talk contribs‎ 8,137 bytes 0‎ →‎Properties
• curprev 18:1018:10, 31 July 2015‎ Sergekorjian talk contribs‎ 8,137 bytes 0‎ →‎Properties
• curprev 18:0918:09, 31 July 2015‎ Sergekorjian talk contribs‎ 8,137 bytes 0‎ →‎Properties
• curprev 18:0918:09, 31 July 2015‎ Sergekorjian talk contribs‎ 8,137 bytes +14‎ →‎Properties
• curprev 18:0818:08, 31 July 2015‎ Sergekorjian talk contribs‎ 8,123 bytes −1‎ →‎Properties
• curprev 18:0818:08, 31 July 2015‎ Sergekorjian talk contribs‎ 8,124 bytes +13‎ →‎Properties
• curprev 18:0618:06, 31 July 2015‎ Sergekorjian talk contribs‎ 8,111 bytes +625‎ →‎Properties
• curprev 18:0418:04, 31 July 2015‎ Sergekorjian talk contribs‎ 7,486 bytes −1‎ No edit summary
• curprev 17:0317:03, 31 July 2015‎ Sergekorjian talk contribs‎ 7,487 bytes −1‎ →‎SPIRE-SI
• curprev 17:0217:02, 31 July 2015‎ Sergekorjian talk contribs‎ 7,488 bytes +890‎ /* Phase III Trials{{cite journal| author=Dadu RT, Ballantyne CM| title=Lipid lowering with PCSK9 inhibitors. | journal=Nat Rev Cardiol | year= 2014 | volume= 11 | issue= 10 | pages= 563-75 | pmid=24958078 | doi=10.1038/nrcardio.2014.84 | pmc= | url=ht...
• curprev 16:5616:56, 31 July 2015‎ Sergekorjian talk contribs‎ 6,598 bytes −563‎ →‎Phase III Trials
• curprev 16:4616:46, 31 July 2015‎ Sergekorjian talk contribs‎ 7,161 bytes −393‎ →‎SPIRE-FH
• curprev 16:4516:45, 31 July 2015‎ Sergekorjian talk contribs‎ 7,554 bytes +131‎ →‎SPIRE-FH
• curprev 16:4416:44, 31 July 2015‎ Sergekorjian talk contribs‎ 7,423 bytes +3‎ →‎SPIRE-HR & SPIRE-LDL
• curprev 16:4116:41, 31 July 2015‎ Sergekorjian talk contribs‎ 7,420 bytes +131‎ →‎SPIRE-HR & SPIRE-LDL
• curprev 16:3816:38, 31 July 2015‎ Sergekorjian talk contribs‎ 7,289 bytes +80‎ →‎SPIRE-2
• curprev 16:3616:36, 31 July 2015‎ Sergekorjian talk contribs‎ 7,209 bytes +87‎ →‎SPIRE-1
• curprev 16:3216:32, 31 July 2015‎ Sergekorjian talk contribs‎ 7,122 bytes +144‎ →‎SPIRE-FH
• curprev 16:3216:32, 31 July 2015‎ Sergekorjian talk contribs‎ 6,978 bytes −1‎ →‎SPIRE-HR & SPIRE-LDL
• curprev 16:3116:31, 31 July 2015‎ Sergekorjian talk contribs‎ 6,979 bytes 0‎ →‎SPIRE-HF
• curprev 16:2716:27, 31 July 2015‎ Sergekorjian talk contribs‎ 6,979 bytes +487‎ →‎Major Trials

1 April 2015

• curprev 22:1822:18, 1 April 2015‎ Madeleine Cochet talk contribs‎ 6,492 bytes 0‎ No edit summary

12 February 2015

• curprev 20:4520:45, 12 February 2015‎ Sergekorjian talk contribs‎ 6,492 bytes +803‎ →‎Properties
• curprev 20:1920:19, 12 February 2015‎ Sergekorjian talk contribs‎ 5,689 bytes +163‎ →‎Phase II Trials
• curprev 20:1720:17, 12 February 2015‎ Sergekorjian talk contribs‎ 5,526 bytes −6‎ →‎Phase II Trials
• curprev 20:1620:16, 12 February 2015‎ Sergekorjian talk contribs‎ 5,532 bytes −135‎ →‎Phase II Trials
• curprev 20:1420:14, 12 February 2015‎ Sergekorjian talk contribs‎ 5,667 bytes +1,172‎ →‎Phase II Trials
• curprev 19:5419:54, 12 February 2015‎ Sergekorjian talk contribs‎ 4,495 bytes +1,572‎ →‎Phase III Trials
• curprev 19:5319:53, 12 February 2015‎ Sergekorjian talk contribs‎ 2,923 bytes +1,734‎ →‎Phase III Trials

11 February 2015

• curprev 20:4220:42, 11 February 2015‎ Sergekorjian talk contribs‎ 1,189 bytes +231‎ →‎Overview

29 September 2014

• curprev 20:5420:54, 29 September 2014‎ Sergekorjian talk contribs‎ 958 bytes +958‎ Created page with "__NOTOC__ File:Pharmacologic-interventions-for-PCSK9.jpg|250px|thumb|right|Pharmacologic interventions for PCSK9 <font size="1">''Adapted from Journal of the American Colle..."